Andrew M. Stern, Ph.D.
|Ph.D. in Biological Chemistry, University of California at Los Angeles|
3501 Fifth Avenue
The overarching goal of our research is to identify mechanisms involved in complex human disease progression and use this knowledge to develop novel therapies for individual patients. We apply a holistic clinically relevant quantitative systems biology and pharmacology approach. This involves the development, implementation, and integration of several high throughput and high content molecular and cell-based technologies and models to comprehensively define fundamental biological processes that are perturbed in particular diseases.
Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, Weir HM, Puhalla SL, Davidson NE, Stern AM, Chu D, Park BH, Lee AV, Oesterreich S. (2017) Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Res 19(1):60.
Gough A, Stern AM, Maier J, Lezon T, Shun TY, Chennubhotla SC, Schurdak ME, Haney SA, Taylor DL. (2017) Biologically Relevant Heterogeneity: Metrics and Practical Insights. SLAS Discov. (3):213-237.
Stern AM, Schurdak ME, Bahar I, Berg JM, Taylor DL (2016) A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine J Biomol Screen 21(6):521-34